“To my ignorant point of view, though, I don't see how Dr P could patent a "treatment pathway."
It’s not an uncommon practice, research the topic and you’ll find many examples. CYDY’s patent for the CCR5 pathway of cancer and their application for the patent of the CCR5/CCL5 treatment pathway for COVID proves that MOA patent for leronlimab is not enough to cover unknown treatment pathways. If the opposite were true, CYDY would not own a patent for the cancer treatment pathway.
Based on previous examples, approval of Incelldx’s patent seems likely. What has yet to be determined is if that patent will benefit either company as leronlimab is not yet approved for COVID.
News 
Market Data 
Discover 
AI
